Alex Arfaei
Recent Quotes
"With a diverse pipeline, including a number of first-in-class drugs in high-potential markets, MRK has significant potential growth drivers."
—
Alex Arfaei, BMO Capital Markets
(2/15/13)
more >
"MRK's MK-8931 is a promising drug that seems to be very effective at lowering beta-amyloid."
—
Alex Arfaei, BMO Capital Markets
(12/3/12)
more >
"MRK is well positioned for steady long-term growth."
—
Alex Arfaei, BMO Capital Markets
(10/28/12)
more >
"MRK is well positioned for steady, long-term growth."
—
Alex Arfaei, BMO Capital Markets
(8/26/12)
more >
"MRK's amended deal with AZ boosts its profit and loss statement."
—
Alex Arfaei, BMO Capital Markets
(7/2/12)
more >
